research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
Search
for
Sort by
Research
30-60 / 1000+ results 
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
research A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.
research Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.
research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data
Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
research Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research The connection of 5-alpha reductase inhibitors to the development of depression
5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
research Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
Finasteride can cause melasma, especially in people with darker skin.
research Association of Suicidality and Depression With 5α-Reductase Inhibitors
Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
research The Effect of 5 -Reductase Inhibitors on Erectile Function
5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
research Algorithmic approach to the treatment of frontal fibrosing alopecia: A systematic review
The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
research 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
5ARI treatment improves hair growth in older men with minimal side effects.
research Medical management of benign prostatic hyperplasia
Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
research 5-alpha reductase inhibitors use in prostatic disease and beyond
5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
research Editor’s picks January 2021
PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
research 5α‐reductase inhibitors: Evaluation of their potential confounding effect on GC‐C‐IRMS doping analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.
research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
research Differential association between cumulative dose of 5α-reductase inhibitors and mortality
Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research Five-alpha-reductase Inhibitors for prostate cancer prevention.
5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
research Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review
5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.